Track Tenaya Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tenaya Therapeutics Inc. Common Stock TNYA · Stock Open Tenaya Therapeutics Inc. Common Stock in new tab

0.3492 USD
EPS
-0.48
P/B
1.46
ROE
-148.16
Beta
2.86
Target Price
3.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 10, 2027
EPS-0.48
Book Value0.24
Price to Book1.46
Debt/Equity5.23
% Insiders0.484%
Estimates
Forward P/E-0.97
Forward EPS-0.36
Target Mean Price3.67

DCF valuation

Model fair value for Tenaya Therapeutics Inc. Common Stock (TNYA)
Result
Sign in to run the valuation for TNYA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 3.67 USD (low 2.00, high 6.00) · as of 15 Nov 2026
Low 2.00
Mean 3.67
High 6.00
Price 0.3492
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Tenaya Therapeutics Inc. Common Stock Logo Tenaya Therapeutics Inc. Common Stock Analysis (TNYA)

United States Health Care Official Website Stock

Is Tenaya Therapeutics Inc. Common Stock a good investment? Tenaya Therapeutics Inc. Common Stock (TNYA) is currently trading at 0.3492 USD. Market analysts have a consensus price target of 3.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Tenaya Therapeutics Inc. Common Stock is expected to release its next earnings report on March 10, 2027. The market consensus estimate for Forward EPS is -0.36.

Investor FAQ

Does Tenaya Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tenaya Therapeutics Inc. Common Stock?

Tenaya Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 10, 2027. The company currently has a trailing EPS of -0.48.

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) TNYA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion